UniQure gets out the gate first in race for Huntington's gene therapy

Biotech company UniQure said Friday it has dosed the first patient with a gene therapy for Huntington's disease, a degenerative condition marked by destruction of nerve cells in the brain. Two patients have entered the trial, one who has received an injection of the therapy into the brain and one who has undergone an imitation procedure.